home / stock / rlay / rlay quote
Last: | $8.90 |
---|---|
Change Percent: | 7.46% |
Open: | $8.31 |
Close: | $8.90 |
High: | $9.02 |
Low: | $8.3 |
Volume: | 2,202,699 |
Last Trade Date Time: | 07/17/2024 03:00:00 am |
Quotes are delayed by 15 to 20 minutes.
Last | Open | Close | High | Low | Volume | Date |
---|---|---|---|---|---|---|
$8.9 | $8.31 | $8.9 | $9.02 | $8.3 | 2,202,699 | 07-17-2024 |
$8.98 | $8.49 | $8.98 | $9.02 | $8.24 | 1,914,765 | 07-16-2024 |
$8.27 | $8.28 | $8.27 | $8.52 | $8.074 | 1,363,914 | 07-15-2024 |
$8.24 | $7.87 | $8.24 | $8.46 | $7.85 | 1,521,563 | 07-12-2024 |
$7.76 | $7.23 | $7.76 | $7.865 | $7.16 | 1,678,269 | 07-11-2024 |
$6.99 | $7 | $6.99 | $7.13 | $6.83 | 613,647 | 07-10-2024 |
$6.94 | $6.46 | $6.94 | $6.95 | $6.37 | 680,253 | 07-09-2024 |
$6.48 | $6.49 | $6.48 | $6.72 | $6.36 | 885,783 | 07-08-2024 |
$6.36 | $6.2 | $6.36 | $6.39 | $6.02 | 600,803 | 07-05-2024 |
$6.27 | $6.52 | $6.27 | $6.55 | $6.16 | 712,350 | 07-04-2024 |
$6.27 | $6.52 | $6.27 | $6.55 | $6.16 | 712,350 | 07-03-2024 |
$6.47 | $6.34 | $6.47 | $6.48 | $5.955 | 3,047,068 | 07-02-2024 |
$6.4 | $6.4 | $6.4 | $6.57 | $6.14 | 1,870,537 | 07-01-2024 |
$6.52 | $6.31 | $6.52 | $6.575 | $6.05 | 3,129,136 | 06-28-2024 |
$6.3 | $6.26 | $6.3 | $6.34 | $6.1022 | 651,736 | 06-27-2024 |
$6.26 | $6.7 | $6.26 | $7.06 | $6.26 | 782,376 | 06-26-2024 |
$6.74 | $6.85 | $6.74 | $6.9295 | $6.72 | 715,854 | 06-25-2024 |
$6.9 | $6.98 | $6.9 | $7.34 | $6.9 | 1,148,875 | 06-24-2024 |
$6.94 | $6.8 | $6.94 | $7.09 | $6.78 | 4,003,458 | 06-21-2024 |
$6.85 | $7 | $6.85 | $7 | $6.44 | 1,310,594 | 06-20-2024 |
News, Short Squeeze, Breakout and More Instantly...
Relay Therapeutics Inc. Company Name:
RLAY Stock Symbol:
NASDAQ Market:
Relay Therapeutics Inc. Website:
2024-06-14 08:36:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
3 new programs include 2 genetic disease programs – vascular malformations & Fabry disease – & 1 precision oncology program – NRAS-specific inhibitor Cash guidance remains unchanged, and is expected to fund operations into second half of 2026 Relay T...
CAMBRIDGE, Mass., June 05, 2024 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage precision medicine company transforming the drug discovery process by combining leading-edge computational and experimental technologies, today announced a clinical trial collabor...